<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9579840</article-id><article-id pub-id-type="pmc">2150165</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bouffet</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Doz</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Demaille</surname><given-names>M. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tron</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Roche</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Plantaz</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thyss</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stephan</surname><given-names>J. L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lejars</surname><given-names>O.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sariban</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Buclon</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Z&#x000c3;&#x000bc;cker</surname><given-names>J. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brunat-Mentigny</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bernard</surname><given-names>J. L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gentet</surname><given-names>J. C.</given-names></name></contrib></contrib-group><aff>Department of Paediatric Oncology, Centre Leon B&#x000c3;&#x000a9;rard, Lyon, France.</aff><pub-date pub-type="ppub"><month>4</month><year>1998</year></pub-date><volume>77</volume><issue>8</issue><fpage>1321</fpage><lpage>1326</lpage><abstract><p>Early detection of relapse has been advocated to improve survival in children with recurrent medulloblastoma. However, the prognostic factors and the longer term outcome of these patients remains unclear. Pattern of recurrences were analysed in three consecutive protocols of the Soci&#x000c3;&#x000a9;t&#x000c3;&#x000a9; Fran&#x000c3;&#x000a7;aise d'Oncologie P&#x000c3;&#x000a9;diatrique (1985-91). A uniform surveillance programme including repeated lumbar puncture combined with computerized tomography (CT) or magnetic resonance imaging (MRI) scan was applied for all registered patients. Forty-six out of 116 patients had progressive or recurrent disease. The median time from diagnosis to recurrence was 10.5 months and 76% relapses occurred during the first 2 years. Seventeen patients had asymptomatic relapses that were detected by the surveillance protocol. Forty-one patients were treated at time of progression. Twenty-three responded to salvage therapy and 11 achieved a second complete remission. The median survival time after progression was 5 months (&#x0003c;1-41 months), and only two patients remained alive at time of follow-up. Length of survival is primarily related to some specific patterns of relapse (time from diagnosis to recurrence, circumstances of relapse, extent of relapse) and to the response to salvage therapy. No evidence of long-term benefit appeared from any form of treatment.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00084-0127.tif" xlink:title="scanned-page" xlink:role="1321" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00084-0128.tif" xlink:title="scanned-page" xlink:role="1322" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00084-0129.tif" xlink:title="scanned-page" xlink:role="1323" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00084-0130.tif" xlink:title="scanned-page" xlink:role="1324" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00084-0131.tif" xlink:title="scanned-page" xlink:role="1325" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00084-0132.tif" xlink:title="scanned-page" xlink:role="1326" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

